Porton Pharma Solutions, a Chongqing, China-headquartered pharmaceutical contract services provider, has partnered with Codexis, a Redwood City, California-headquartered protein engineering and biocatalyst company, to use Codexis’ biocatalyst technology for Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business.

Under the collaboration, Codexis will license core elements of its biocatalyst technologies to Porton, including its proprietary biocatalyst libraries, high-throughput screening, and enzyme manufacturing knowledge. Codexis will also provide preferential access to its CodeEvolver protein engineering platform technology for the creation of new biocatalytic process services. Porton will install new operations to drive adoption and application of these biocatalyst technologies into its custom contract development and manufacturing offerings. Additionally, Porton pledges financial commitments to use Codexis’ CodeEvolver protein-engineering platform technology.

Source: Codexis